bitBiome adopts TeselaGen's AI-powered platform to run its strain-engineering and lab-automation workflows, linking single-cell genomic intelligence to the experiments that turn it into products
PORTOLA VALLEY, Calif. and TOKYO, Nov. 12, 2026 /PRNewswire-PRWeb/ -- TeselaGen Biotechnology Inc., the AI-powered platform for designing, building, testing and optimizing biological systems, today announced a collaboration with bitBiome, Inc., an AI-native biotechnology company transforming the world's microbial diversity into predictive biological intelligence. bitBiome has deployed the TeselaGen platform across its research teams to manage strain engineering, sample tracking and automated lab workflows, connecting the designs produced by its AI and genomic data platform to the experimental results that validate them.
bitBiome builds proprietary genomic datasets from individual microbial cells with its bit-MAP® single-cell sequencing technology. Those data feed bit-GEM, their sequence catalog, and SENS-AI, their AI model for designing and optimizing enzymes and strains. Each design still has to be built, tested and measured in the lab using their high-throughput sequence and whole genome editing platform bit-EVO, and the value of the AI grows with every result that feeds back into it. TeselaGen provides that operational layer: a single system of record for constructs, strains, samples and plates, electronic lab notebooks, and configurable workflows that carry each experiment from design to data.
Over the course of 2026, TeselaGen and bitBiome teams worked together to model bitBiome's strain-engineering and automation workflows on the platform. "bitBiome is building one of the most distinctive microbial data assets in the world, and AI models are only as good as the experimental loop behind them," said Eduardo Abeliuk, Ph.D., CEO of TeselaGen. "Our job is to make that loop fast and traceable, so every strain bitBiome designs is built, tested and fed back into its models with full context. Working side by side with their team has made our platform better for every lab that runs design-build-test-learn at scale."
"Our AI platform designs enzymes and strains from our proprietary data that cannot be found in the public databases. Turning those designs into results for our partners depends largely on how efficiently we can test those designs in the lab. TeselaGen gave us a platform our scientists could shape around their own workflows, and a team that moved at our pace," said Yuji Suzuki, CEO, bitBiome.
bitBiome partners with companies including Twist Bioscience, Ajinomoto, Tojo Vikas, and Kyoritsu Seiyaku, on enzyme and strain development for life science, food, materials, animal health and other biomanufacturing applications. The TeselaGen platform supports this partnered work by giving each program a consistent, auditable record from sequence to result.
About TeselaGen Biotechnology Inc.
TeselaGen is building an artificial intelligence-powered enterprise platform for designing, building, testing and optimizing biological systems. TeselaGen's cloud-based platform, which includes Tesela Copilot, an AI agent for life science research, bridges the gap between good ideas and the realization of valuable products like vaccines, biologic medicines and sustainably sourced chemicals. TeselaGen is privately held and based in Silicon Valley, CA. The company has received four US National Science Foundation funding awards, a US Department of Energy funding award, CORFO awards and a Bio-IT World Best Practices Award, and holds patents on using artificial intelligence to accelerate biotech product development. Follow TeselaGen on X and LinkedIn and learn more at teselagen.com.
About bitBiome, Inc.
bitBiome is a data and AI company building the intelligence layer for the next era of biotechnology. Founded in 2018 as a spin-out of Waseda University in Tokyo, bitBiome uses its bit-MAP® microbial single-cell sequencing technology to build bit-GEM, a proprietary sequence catalog drawn from the planet's microbial diversity, and applies AI through bit-EVO and SENS-AI to design and optimize enzymes and strains for biomanufacturing. bitBiome has raised over $45 million in private and public funding and has offices in Tokyo, Japan, and Palo Alto, California. Learn more at bitbiome.bio.
Media Contact
Eduardo Abeliuk, TeselaGen Biotechnology Inc., 1 510-761-7938, [email protected], https://teselagen.com/
Laura Shelton, bitBiome, [email protected], https://bitbiome.bio/
SOURCE TeselaGen Biotechnology Inc.
Share this article